{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-012336","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.996733+00:00","generated_at":"2026-06-10T08:00:08.449367+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palatin reports FY2023 net loss $27.5M; Vyleesi net revenue up 298%; PL9643 fully enrolled","bullets":["Net loss of $27.5M ($2.53 diluted EPS) for FY2023 vs $36.2M loss ($3.79 EPS) in FY2022.","Vyleesi net product revenue $4.9M in FY2023, up 298% YoY; Q4 net revenue $1.8M, up 128%.","Phase 3 PL9643 (dry eye) fully enrolled (570 patients); topline data expected late Q4 2023.","Phase 2 PL8177 (ulcerative colitis) interim analysis targeted Q1 2024; topline H1 2024.","Cash $11.0M plus $2.9M receivables as of June 30; audit includes going concern paragraph."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-012336","json":"https://secwatch.observer/filing/0001654954-23-012336.json","markdown":"https://secwatch.observer/filing/0001654954-23-012336.md","text":"https://secwatch.observer/filing/0001654954-23-012336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423012336/0001654954-23-012336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423012336/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:00:08.449367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a1709e9dd3ea03c1661caa8a69e85edd806e65f","claim":"PALATIN TECHNOLOGIES INC reported financial results for fiscal year ended June 30, 2023.","evidence_excerpt":"On September 28, 2023, we issued a press release including results for our fiscal year ended June 30, 2023 and announcing a teleconference and webcast to be held September 28, 2023, at 11:00 a.m. Eastern time, which will include a discussion on results of operations in greater detail and an update on corporate developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/911216/000165495423012336/0001654954-23-012336-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8475ad10df534bfa504fcdcccb8c3d0ec9379f9d","claim":"PALATIN TECHNOLOGIES INC reported financial results for fiscal fourth quarter ended June 30, 2023.","evidence_excerpt":"Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/911216/000165495423012336/0001654954-23-012336-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal fourth quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}